Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Open Forum Infectious Diseases|June 24, 2026
Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure InfectionsJessica Howard-Anderson, Toshimitsu Hamasaki, Lizhao Ge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reductionKala Visvanathan, Rowan T Chlebowski, Patricia Hurley, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2022
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical TrialsJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)William M Sikov, Donald A Berry, Charles M Perou, et al.Annals of Surgical Oncology|July 27, 2025
Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL StudyShoshana M Rosenberg, Christel Rushing, Kristin L Schreiber, et al.Cell|November 18, 2017
Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder ConsensusRobert B Conley, Dane Dickson, Jean Claude Zenklusen, et al.BMJ (Clinical Research Ed.)|October 30, 2023
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort studyRenée S J M Schmitz, Alexandra W van den Belt-Dusebout, Karen Clements, et al.JAMA Oncology|December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical TrialAnn H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast CancerJonathan H Shepherd, Karla Ballman, Mei-Yin C Polley, et al.NPJ Breast Cancer|May 6, 2026
Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoringS Doyle, M A Oerlemans, J Brunekreef, et al.Pageof 6